Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 17845743)

1.

Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools.

Karagianis J, Rosenbluth M, Tohen M, Ascher-Svanum H, Treuer T, de Lima MS, Citrome L.

Curr Med Res Opin. 2007 Oct;23(10):2551-7. Review. Erratum in: Curr Med Res Opin. 2011 Apr;27(4):835-6.

PMID:
17845743
2.
3.

Can contraindications compromise evidence-based, patient-centered clinical practice?

Montori VM, Leung TW, Devereaux PJ, Schünemann HJ, Akl EA, Gafni A, Guyatt GH.

Can J Clin Pharmacol. 2006 Winter;13(1):e92-101. Epub 2006 Feb 1.

4.

Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care.

Nasrallah HA, Newcomer JW.

J Clin Psychopharmacol. 2004 Oct;24(5 Suppl 1):S7-14.

PMID:
15356415
5.

Going off-label without venturing off-course: evidence and ethical off-label prescribing.

Largent EA, Miller FG, Pearson SD.

Arch Intern Med. 2009 Oct 26;169(19):1745-7. doi: 10.1001/archinternmed.2009.314. No abstract available.

PMID:
19858430
6.
7.

Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.

Foussias G, Remington G.

Can J Psychiatry. 2010 Mar;55(3):117-25. Review.

PMID:
20370961
8.

What do large scale studies of medication in schizophrenia add to our management strategies?

Agius M, Davis A, Gilhooley M, Chapman S, Zaman R.

Psychiatr Danub. 2010 Jun;22(2):323-8. Review.

9.

Factors affecting feasibility and acceptability of a practice-based educational intervention to support evidence-based prescribing: a qualitative study.

Watkins C, Timm A, Gooberman-Hill R, Harvey I, Haines A, Donovan J.

Fam Pract. 2004 Dec;21(6):661-9. Epub 2004 Nov 4.

10.

Antipsychotics and metabolics in the post-CATIE era.

Meyer JM.

Curr Top Behav Neurosci. 2010;4:23-42. Review.

PMID:
21312396
11.
12.

Practice-based evidence for clinical practice improvement: an alternative study design for evidence-based medicine.

Horn SD, Gassaway J, Pentz L, James R.

Stud Health Technol Inform. 2010;151:446-60.

PMID:
20407178
13.

Improving effectiveness in communicating risk to patients.

Burkiewicz JS, Vesta KS, Hume AL.

Consult Pharm. 2008 Jan;23(1):37-43. Review.

PMID:
18284317
14.

Creating synergy in practice: promoting complementarity between evidence-based and postmodern approaches.

Jacobs S, Kissil K, Scott D, Davey M.

J Marital Fam Ther. 2010 Apr;36(2):185-96. doi: 10.1111/j.1752-0606.2009.00171.x. Review.

PMID:
20433595
15.

Suicide in schizophrenia, clozapine, and adoption of evidence-based medicine.

Meltzer HY.

J Clin Psychiatry. 2005 Apr;66(4):530-3. Review. No abstract available.

PMID:
15816797
16.

Evidence-based practice strategies for cardiovascular care.

Hatfield L, Mulvey S, Marleau-Webb A, Bower L, Polomano RC.

J Cardiovasc Manag. 2004 May-Jun;15(3):10-9.

PMID:
15216605
17.

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA.

Schizophr Bull. 2003;29(1):15-31.

18.

Assessing potential risks and evaluating expected benefits.

Shaya FT, Gu A.

Manag Care Interface. 2005 May;18(5):27-30.

PMID:
15941187
19.

Providing safe medicines for children in Nigeria: The impediments and remedies.

Oshikoya KA, Senbanjo IO.

Ann Afr Med. 2010 Oct-Dec;9(4):203-12. doi: 10.4103/1596-3519.70954. Review.

20.

Guidelines--are they useful?

Ben-Menachem E, French JA.

Epilepsia. 2006;47 Suppl 1:62-4.

PMID:
17044829
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk